233276-38-5

Usage

Uses

Used in Organic Synthesis:
2H-Pyran-4-carboxylic acid, tetrahydro-4-methyl-(9CI) is used as a building block in organic synthesis for the creation of various compounds. Its unique structure and functional groups make it a versatile component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2H-Pyran-4-carboxylic acid, tetrahydro-4-methyl-(9CI) is used as a key intermediate in the development of new drugs. Its potential biological activities and pharmacological properties are being explored for the treatment of various diseases and conditions.
Used in Medicinal Applications:
2H-Pyran-4-carboxylic acid, tetrahydro-4-methyl-(9CI) is being studied for its potential medicinal applications due to its biological activities. Researchers are investigating its therapeutic potential in the development of new medications for various health issues.

Upstream product

• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 74-88-4 methyl iodide 
• 443912-70-7 methyl 4-methyltetrahydro-2H-pyran-4-carboxylate 
• 856255-87-3 4-methyltetrahydro-2H-pyran-4-carbonitrile 
• 134419-59-3 4-oxanyl methanesulfonate 
• 848821-06-7 4-cyanotetrahydro-2H-pyran-4-carboxylic acid 
• 25637-16-5 4-bromotetrahydro-2H-pyran 
• 97986-34-0 toluene-4-sulfonic acid tetrahydropyran-4-yl ester 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 871022-58-1 benzyl tetrahydro-2H-pyran-4-carboxylate 

Downstream Products

• 693245-65-7 4-methyltetrahydro-2H-pyran-4-amine 
• 887481-28-9 1-(4-methyltetrahydro-2H-pyran-4-yl)ethan-1-one 

Relevant academic research and scientific papers

NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST

The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; R1 represents an optionally substituted alkyl group or the like; R2 represents a halogen atom or the like; and R3 is an alkyl group substituted with an optionally substituted aryl group or the like, and R4 is a hydrogen atom or the like; or R3 and R4 are terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof.

4-substituted or unsubstituted tetrahydropyran-4-carboxylic acid or its ester compound compd.

A process for producing a 4-(un)substituted tetrahydropyran-4-carboxylic acid compound or an ester compound thereof which are represented by the formula (1): (1) (wherein R represents hydrogen or a hydrocarbon group; R represents hydrogen or an optionally substituted hydrocarbon group; and R represents hydrogen or a hydrocarbon group), characterized by reacting a 4-(un)substituted 4-cyanotetrahydropyran compound represented by the formula (2): (2) (wherein R and R are the same as defined above) with water or an alcohol which are represented by the formula (3): ROH (3) (wherein R is the same as defined above) in the presence of an acid or base.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK2 receptor antagonists

Herein we describe the synthesis of a series of new potent tachykinin NK2 receptor antagonists by the modulation of the Cand N-terminal moieties of ibodutant (MEN 15596, 1). The Nterminal benzo[b]thiophene ring was replaced by different substituted naphthalenes and benzofurans, while further modifications were evaluated at the C-terminal tetrahydropyran moiety. Most compounds demonstrated a high affinity for the human NK2 receptor and high in vitro antagonist potency, indicating that a wide range of substituents at both termini can be incorporated in the molecule without detrimental effects on the interactions with the NK2 receptor. Selected compounds were tested in vivo confirming their activity as NK2 antagonists. In particular, after both iv and id administration to guinea pig, compound 61b was able to antagonize NK2-induced colonic contractions with a potency and duration-of-action fully comparable to the reference compound 1 (MEN 15596, ibodutant).

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I) and salts thereof are provided: formula (I) wherein R4, R5, R6, Q, A, and Y are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treatin

Triazolo-pyridazine derivatives as ligands for GABA receptors

1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing a fluoro-substituted phenyl ring at the 3-position and a heteroaryl-alkoxy moiety at the 6-position, are selective ligands for GABAAreceptors, in particular having high affinity for the α2